Johnson & Johnson $JNJ Shares Sold by QRG Capital Management Inc.

QRG Capital Management Inc. decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 34.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 352,051 shares of the company’s stock after selling 187,772 shares during the quarter. Johnson & Johnson comprises 0.8% of QRG Capital Management Inc.’s investment portfolio, making the stock its 17th largest holding. QRG Capital Management Inc.’s holdings in Johnson & Johnson were worth $65,277,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Evolution Wealth Management Inc. purchased a new stake in Johnson & Johnson during the 2nd quarter valued at approximately $27,000. Clayton Financial Group LLC purchased a new position in shares of Johnson & Johnson in the 3rd quarter valued at approximately $28,000. Semmax Financial Advisors Inc. increased its holdings in shares of Johnson & Johnson by 55.0% in the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock valued at $31,000 after purchasing an additional 72 shares during the period. GFG Capital LLC purchased a new stake in shares of Johnson & Johnson during the second quarter worth approximately $35,000. Finally, Signature Resources Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 262.9% during the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock worth $47,000 after purchasing an additional 184 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Jim Cramer publicly praised J&J, highlighting its diversified businesses and steady cash flows — a high‑profile endorsement that can attract retail flows and support the stock. Jim Cramer Just Can’t Stop Praising Johnson & Johnson (JNJ)
• Positive Sentiment: J&J is featured in dividend-focused lists as a reliable income name, reinforcing demand from income investors given its yield and long dividend history. 3 Dividend Stocks to Own No Matter Where the Market Moves in 2026
• Positive Sentiment: Zacks highlighted J&J in its investment ideas feature, keeping the stock on investors’ radar as a large-cap healthcare pick. Zacks Investment Ideas feature highlights: Netflix, Intel and Johnson & Johnson
• Neutral Sentiment: Benzinga flags a “$10 billion test” in J&J’s 2026 outlook — management’s guidance and 2026 execution will be pivotal in the Q4 print and could swing sentiment either way. Johnson & Johnson’s $10 Billion Test: 2026 Outlook Could Make Or Break JNJ Heading Into Q4
• Neutral Sentiment: Analyst previews (Zacks, TipRanks, others) show mixed views: strong pharma and MedTech momentum but pressure from Stelara biosimilar competition and China headwinds — earnings will clarify the balance. Should You Buy, Sell or Hold J&J Stock Ahead of Q4 Results?
• Neutral Sentiment: Pre‑earnings pieces (TipRanks/MarketBeat) note analysts expect modest revenue growth into Q4; some investors are using hedged exposure strategies ahead of the release to limit risk. Is Johnson & Johnson (JNJ) Stock a Buy Ahead of Q4 Earnings?
• Negative Sentiment: Seeking Alpha warns that a sizable 2025 downgrade has tempered expectations; lowered growth assumptions can keep a lid on valuation and increase downside risk if guidance disappoints. Johnson & Johnson: Tempering Expectations After A Massive 2025 (Downgrade)
• Negative Sentiment: Bank of America reiterated a Hold rating, signaling limited near‑term upside in analysts’ view and potentially constraining momentum from bullish headlines. Bank of America Securities Sticks to Their Hold Rating for Johnson & Johnson (JNJ)

Johnson & Johnson Stock Down 0.3%

JNJ stock opened at $218.81 on Tuesday. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. Johnson & Johnson has a 12 month low of $141.50 and a 12 month high of $220.11. The firm has a market capitalization of $527.18 billion, a PE ratio of 21.12, a P/E/G ratio of 2.25 and a beta of 0.34. The company’s 50 day simple moving average is $206.43 and its 200-day simple moving average is $187.62.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.4%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio is currently 50.19%.

Analyst Upgrades and Downgrades

Several analysts have recently weighed in on the stock. Wells Fargo & Company lifted their target price on shares of Johnson & Johnson from $212.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, December 12th. Barclays increased their target price on Johnson & Johnson from $197.00 to $217.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 30th. Royal Bank Of Canada set a $240.00 price objective on Johnson & Johnson in a report on Wednesday, December 17th. Wolfe Research boosted their target price on shares of Johnson & Johnson from $225.00 to $240.00 and gave the stock an “outperform” rating in a research report on Monday, January 5th. Finally, The Goldman Sachs Group increased their target price on shares of Johnson & Johnson from $213.00 to $240.00 and gave the company a “buy” rating in a report on Thursday, December 18th. Four analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $213.33.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.